ReviewExtracellular vesicles and circulating nucleic acids2026
Aptamer-based technologies for extracellular vesicle analysis and engineering: from isolation to functional applications.
Review in Extracellular vesicles and circulating nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs) are natural mediators of intercellular communication and hold promise for disease diagnosis and drug delivery, yet their intrinsic heterogeneity complicates isolation, molecular profiling, and targeted delivery. Aptamers, owing to their high affinity, specificity, chemical tunability, and scalable synthesis, offer a flexible molecular toolkit to address these challenges. In this review, we highlight recent progress in integrating aptamers into EV research across three interconnected domains: (1) the selection of aptamers against EV-associated surface markers; (2) the development of aptamer-based methods for EV capture and isolation; (3) the use of aptamer-functionalized EVs for targeted drug delivery and immunomodulation. We also discuss outstanding challenges, particularly the need for selection strategies that better preserve native EV epitope conformations and the rational design of multifunctional aptamer architectures. Looking forward, the convergence of aptamer technology with EV biology is expected to enable aptamer-drug conjugates and minimally invasive, dynamic liquid biopsy approaches for major diseases such as cancer, ultimately advancing early diagnosis and precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.